Viking Global Opportunities GP LLC
CIK 0001629476 Name as filed on the most recent filing
Filed as Viking Global Opportunities GP LLC (45)
107 transaction lines · from 45 filings · filed 2016-02-08 to 2025-10-09 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Inhibrx Biosciences, Inc. 1 filings
- ISSUER BridgeBio Pharma, Inc. 4 filings
- ISSUER APi Group Corp 3 filings
- ISSUER 4D Molecular Therapeutics, Inc. 3 filings
- ISSUER RayzeBio, Inc. 1 filings
- ISSUER Inhibrx, Inc. 4 filings
- ISSUER Roivant Sciences Ltd. 1 filings
- ISSUER Frazier Lifesciences Acquisition Corp 1 filings
- ISSUER Amylyx Pharmaceuticals, Inc. 2 filings
- ISSUER Procept BioRobotics Corp 2 filings
- ISSUER Figs, Inc. 1 filings
- ISSUER Rallybio Corp 1 filings
- ISSUER Zentalis Pharmaceuticals, Inc. 2 filings
- ISSUER Adaptive Biotechnologies Corp 3 filings
- ISSUER Urovant Sciences Ltd. 9 filings
- ISSUER Myovant Sciences Ltd. 2 filings
- ISSUER Axovant Sciences Ltd. 3 filings
- ISSUER Editas Medicine, Inc. 2 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2025-10-07 |
Inhibrx Biosciences, Inc. INBX |
S, Open-market sale | 308,643 disposed | 32.25 | 9,953,736.75 | Form 4, filing 0000905148-25-003555 | |
| 2025-10-07 |
Inhibrx Biosciences, Inc. INBX |
S, Open-market sale | 25,042 disposed | 32.25 | 807,604.50 | Form 4, filing 0000905148-25-003555 | |
| 2025-10-07 |
Inhibrx Biosciences, Inc. INBX |
S, Open-market sale | 16,315 disposed | 32.25 | 526,158.75 | Form 4, filing 0000905148-25-003555 | |
| 2025-06-27 |
BridgeBio Pharma, Inc. BBIO |
S, Open-market sale | 3,500,000 disposed | 44.00 | 154,000,000.00 | Form 4, filing 0000905148-25-002297 | |
| 2025-01-31 |
BridgeBio Pharma, Inc. BBIO |
S, Open-market sale | 3,065,616 disposed | 34.90 | 106,989,998.40 | Form 4, filing 0000905148-25-000306 | |
| 2024-06-17 |
APi Group Corp APG |
S, Open-market sale | 1,912,750 disposed | 38.15 | 72,971,412.50 | Form 4, filing 0000905148-24-001733 | |
| 2024-06-17 |
APi Group Corp APG |
S, Open-market sale | 39,032 disposed | 38.15 | 1,489,070.80 | Form 4, filing 0000905148-24-001733 | |
| 2024-03-05 |
APi Group Corp APG |
S, Open-market sale | 2,977,845 disposed | 34.25 | 101,991,191.25 | Form 4, filing 0000905148-24-000920 | |
| 2024-03-05 |
APi Group Corp APG |
S, Open-market sale | 60,772 disposed | 34.25 | 2,081,441.00 | Form 4, filing 0000905148-24-000920 | |
| 2024-01-04 |
4D Molecular Therapeutics, Inc. FDMT |
S, Open-market sale | 540,000 disposed | 19.53 | 10,546,200.00 | Form 4, filing 0000905148-24-000092 | |
| 2024-01-02 |
APi Group Corp APG |
S, Open-market sale | 6,300,817 disposed | 31.30 | 197,215,572.10 | Form 4, filing 0000905148-24-000080 | |
| 2024-01-02 |
APi Group Corp APG |
S, Open-market sale | 195,200 disposed | 31.30 | 6,109,760.00 | Form 4, filing 0000905148-24-000080 | |
| 2024-01-02 |
APi Group Corp APG |
S, Open-market sale | 3,983 disposed | 31.30 | 124,667.90 | Form 4, filing 0000905148-24-000080 | |
| 2023-09-19 |
RayzeBio, Inc. RYZB |
P, Open-market purchase | 930,556 acquired | 18.00 | 16,750,008.00 | Form 4, filing 0000905148-23-000958 | |
| 2023-09-19 |
RayzeBio, Inc. RYZB |
P, Open-market purchase | 458,333 acquired | 18.00 | 8,249,994.00 | Form 4, filing 0000905148-23-000958 | |
| 2023-08-28 |
Inhibrx, Inc. INBX |
P, Open-market purchase | 511,627 acquired | 19.35 | 9,899,982.45 | Form 4, filing 0000905148-23-000804 | |
| 2023-07-18 |
BridgeBio Pharma, Inc. BBIO |
S, Open-market sale | 1,500,000 disposed | 35.00 | 52,500,000.00 | Form 4, filing 0001140361-23-035288 | |
| 2023-06-22 |
Roivant Sciences Ltd. ROIV |
S, Open-market sale | 5,427,043 disposed | 9.90 | 53,727,725.70 | Form 4, filing 0001140361-23-031459 | |
| 2023-06-22 |
Roivant Sciences Ltd. ROIV |
S, Open-market sale | 5,236,006 disposed | 9.90 | 51,836,459.40 | Form 4, filing 0001140361-23-031459 | |
| 2023-06-22 |
Roivant Sciences Ltd. ROIV |
S, Open-market sale | 2,226,195 disposed | 9.90 | 22,039,330.50 | Form 4, filing 0001140361-23-031459 | |
| 2023-06-22 |
Roivant Sciences Ltd. ROIV |
S, Open-market sale | 110,756 disposed | 9.90 | 1,096,484.40 | Form 4, filing 0001140361-23-031459 | |
| 2023-05-09 |
4D Molecular Therapeutics, Inc. FDMT |
P, Open-market purchase | 850,000 acquired | 16.00 | 13,600,000.00 | Form 4, filing 0001140361-23-024202 | |
| 2022-11-02 |
Frazier Lifesciences Acquisition Corp FLAC |
P, Open-market purchase | 567,532 acquired | 10.08 | 5,720,722.56 | Form 4, filing 0001140361-22-040057 | |
| 2022-11-02 |
Frazier Lifesciences Acquisition Corp FLAC |
P, Open-market purchase | 279,530 acquired | 10.08 | 2,817,662.40 | Form 4, filing 0001140361-22-040057 | |
| 2022-10-07 |
Inhibrx, Inc. INBX |
P, Open-market purchase | 1,000,000 acquired | 30.00 | 29,999,900.00 | Form 4, filing 0001140361-22-036956 | |
| 2022-10-07 |
Inhibrx, Inc. INBX |
P, Open-market purchase | 333,333 acquired | 30.00 | 9,999,956.67 | Form 4, filing 0001140361-22-036956 | |
| 2022-09-09 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 312,353 disposed | 29.87 | 9,329,265.70 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-09 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 156,463 disposed | 30.90 | 4,834,127.79 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-09 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 147,502 disposed | 29.87 | 4,405,545.49 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-09 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 73,886 disposed | 30.90 | 2,282,804.02 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-09 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 6,654 disposed | 31.44 | 209,217.73 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-09 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 3,142 disposed | 31.44 | 98,792.02 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 159,026 disposed | 29.14 | 4,634,431.11 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 111,102 disposed | 32.23 | 3,580,773.02 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 108,631 disposed | 28.16 | 3,058,581.85 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 80,715 disposed | 27.28 | 2,202,090.84 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 75,096 disposed | 29.14 | 2,188,492.69 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 52,466 disposed | 32.23 | 1,690,958.19 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 51,298 disposed | 28.16 | 1,444,331.10 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 38,116 disposed | 27.28 | 1,039,892.15 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 15,996 disposed | 30.59 | 489,277.65 | Form 4, filing 0001140361-22-032970 | |
| 2022-09-08 |
Amylyx Pharmaceuticals, Inc. AMLX |
S, Open-market sale | 7,554 disposed | 30.59 | 231,057.98 | Form 4, filing 0001140361-22-032970 | |
| 2022-03-18 |
Procept BioRobotics Corp PRCT |
S, Open-market sale | 1,147,205 disposed | 29.90 | 34,301,429.50 | Form 4, filing 0000905148-22-000308 | |
| 2022-03-18 |
Procept BioRobotics Corp PRCT |
S, Open-market sale | 101,795 disposed | 29.90 | 3,043,670.50 | Form 4, filing 0000905148-22-000308 | |
| 2022-01-11 |
Amylyx Pharmaceuticals, Inc. AMLX |
P, Open-market purchase | 2,300,000 acquired | 19.00 | 43,700,000.00 | Form 4, filing 0001140361-22-001654 | |
| 2021-09-17 |
Procept BioRobotics Corp PRCT |
P, Open-market purchase | 400,000 acquired | 35.00 | 14,000,000.00 | Form 4, filing 0001567619-21-017393 | |
| 2021-09-03 |
Figs, Inc. FIGS |
S, Open-market sale | 42,413 disposed | 44.92 | 1,905,191.96 | Form 4, filing 0001567619-21-016763 | |
| 2021-09-02 |
Figs, Inc. FIGS |
S, Open-market sale | 157,587 disposed | 47.28 | 7,450,713.36 | Form 4, filing 0001567619-21-016763 | |
| 2021-07-29 |
Rallybio Corp RLYB |
P, Open-market purchase | 806,000 acquired | 13.00 | 10,478,000.00 | Form 4, filing 0001387131-21-007995 | |
| 2020-12-15 |
4D Molecular Therapeutics Inc. FDMT |
P, Open-market purchase | 1,100,000 acquired | 23.00 | 25,300,000.00 | Form 4, filing 0001387131-20-011272 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Viking Global Opportunities GP LLC, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001629476
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6